GGrantIndex
← Leaderboards

Louise C Showe

Wistar Institute

$10,986,130
Attributed
$12,994,667
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200523
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$12,994,667 · 10

By mechanism

U01$6,154,318 · 2
R01$3,433,946 · 2
P30$2,490,171 · 3
R21$511,582 · 2
S10$404,650 · 1

Top collaborators

Most similar at Wistar Institute

Same institution · by research overlap

Others in their field

Top investigators on “Gene Expression

Research focus

Gene ExpressionSamplingBaseResponseGenesResearch PersonnelCellsMicrornasEarly DiagnosisTrainingGene Expression ProfilingMalignant NeoplasmsDiagnosisScreeningMalignant Neoplasm Of LungAreaMicroarray AnalysisGene Expression ProfileGenomicsServicesFundingMessenger RnaTechnologyMethylation

Grant awards (35)

Genomics Shared Resource$221,010
P30 · FY2023 · CA · contact PI
Genomics Shared Resource$221,010
P30 · FY2022 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$448,182
U01 · FY2021 · CA · contact PI
Genomics Shared Resource$221,010
P30 · FY2021 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$608,274
U01 · FY2020 · CA · contact PI
Genomics Shared Resource$205,228
P30 · FY2020 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$819,590
U01 · FY2019 · CA · contact PI
Bioinformatics Shared Resource$263,055
P30 · FY2019 · CA · contact PI
Genomics Shared Resource$221,010
P30 · FY2019 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$786,485
U01 · FY2018 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$671,654
U01 · FY2017 · CA · contact PI
Development of circulating biomarker for lung cancer$193,212
R21 · FY2017 · CA · contact PI
Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer$682,890
U01 · FY2016 · CA · contact PI
HDAC Inhibitors and CTCL$390,140
R01 · FY2013 · CA · contact PI
Genomics Facility$206,274
P30 · FY2013 · CA · contact PI
HDAC Inhibitors and CTCL$423,039
R01 · FY2012 · CA · contact PI
Genomics Facility$224,915
P30 · FY2012 · CA · contact PI
HDAC Inhibitors and CTCL$396,309
R01 · FY2011 · CA · contact PI
Genomics Facility$225,853
P30 · FY2011 · CA · contact PI
HDAC Inhibitors and CTCL$406,113
R01 · FY2010 · CA · contact PI
Genomics Facility$246,137
P30 · FY2010 · CA · contact PI
HDAC Inhibitors and CTCL$415,059
R01 · FY2009 · CA · contact PI
Genomics Facility$234,669
P30 · FY2009 · CA · contact PI
Comprehensive genomics using the Illumina Beadstation 500$404,650
S10 · FY2008 · RR · contact PI
Microarray Analysis of Responsiveness of CTCL IL-12$157,910
R01 · FY2008 · CA · contact PI
Microarray Analysis of Responsiveness of CTCL IL-12$306,522
R01 · FY2007 · CA · contact PI
Microarray Analysis of Responsiveness of CTCL IL-12$311,770
R01 · FY2006 · CA · contact PI
Microarray Analysis of Responsiveness of CTCL IL-12$315,409
R01 · FY2005 · CA
Microarray Analysis of Responsiveness of CTCL IL-12$311,675
R01 · FY2004 · CA
CTCL STAGING USING GENE EXPRESSION PROFILES$510,680
U01 · FY2003 · CA
CTCL STAGING USING GENE EXPRESSION PROFILES$502,278
U01 · FY2002 · CA
CTCL STAGING USING GENE EXPRESSION PROFILES$616,308
U01 · FY2001 · CA
GENE EXPRESSION IN CTCL PATIENTS IN IL 12 CLINICAL TRIAL$157,466
R21 · FY2001 · CA
CTCL STAGING USING GENE EXPRESSION PROFILES$507,977
U01 · FY2000 · CA
GENE EXPRESSION IN CTCL PATIENTS IN IL 12 CLINICAL TRIAL$160,904
R21 · FY2000 · CA